Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract

Yi Wen Wang, Wei Ming Li, Wen Jeng Wu, Chee Yin Chai, Tsuey Yu Chang, Yin Sun, Chih Jen Cheng, Yow Ling Shiue, Shu Jem Su, Hong Lin Cheng, Hsiao-Sheng Liu, Nan Haw Chow

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Upper urinary tract urothelial carcinoma is a relatively uncommon disease and is diagnosed more frequently at advanced stages. The prognosis of these patients mainly has been related to tumor stage and grade. As a result, the definition of prognostic indicators enabling precise patient selection is mandatory for neoadjuvant or adjuvant therapies. The epithelial membrane protein (EMP2) was identified as one of the up-regulated genes by isoflavones. EMP2 overexpression suppressed foci formation, anchorage-independent growth in vitro, and tumorigenicity in severe combined immunodeficiency mice (all P < 0.05). In addition, a cross-talk between EMP2 and integrins αV and β3 was shown in the regulation of cell adhesion and migration. Higher EMP2 expression was associated with a better progression-free survival (P = 0.008) and cancer-related death (P < 0.001). EMP2 was identified as a tumor-suppressor gene in urinary tract urothelial carcinoma and may be an innovative co-targeting candidate for designing integrin-based cancer therapy.

Original languageEnglish
Pages (from-to)709-719
Number of pages11
JournalAmerican Journal of Pathology
Volume183
Issue number3
DOIs
Publication statusPublished - 2013 Sep 1

Fingerprint

Urinary Tract
Membrane Proteins
Carcinoma
Integrins
Severe Combined Immunodeficiency
Neoplasms
Isoflavones
Tumor Suppressor Genes
Cell Adhesion
Patient Selection
Disease-Free Survival
Cell Movement
Therapeutics
Growth
Genes

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Wang, Yi Wen ; Li, Wei Ming ; Wu, Wen Jeng ; Chai, Chee Yin ; Chang, Tsuey Yu ; Sun, Yin ; Cheng, Chih Jen ; Shiue, Yow Ling ; Su, Shu Jem ; Cheng, Hong Lin ; Liu, Hsiao-Sheng ; Chow, Nan Haw. / Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract. In: American Journal of Pathology. 2013 ; Vol. 183, No. 3. pp. 709-719.
@article{b849ca3b3c1e4a0ba194093b5d88459e,
title = "Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract",
abstract = "Upper urinary tract urothelial carcinoma is a relatively uncommon disease and is diagnosed more frequently at advanced stages. The prognosis of these patients mainly has been related to tumor stage and grade. As a result, the definition of prognostic indicators enabling precise patient selection is mandatory for neoadjuvant or adjuvant therapies. The epithelial membrane protein (EMP2) was identified as one of the up-regulated genes by isoflavones. EMP2 overexpression suppressed foci formation, anchorage-independent growth in vitro, and tumorigenicity in severe combined immunodeficiency mice (all P < 0.05). In addition, a cross-talk between EMP2 and integrins αV and β3 was shown in the regulation of cell adhesion and migration. Higher EMP2 expression was associated with a better progression-free survival (P = 0.008) and cancer-related death (P < 0.001). EMP2 was identified as a tumor-suppressor gene in urinary tract urothelial carcinoma and may be an innovative co-targeting candidate for designing integrin-based cancer therapy.",
author = "Wang, {Yi Wen} and Li, {Wei Ming} and Wu, {Wen Jeng} and Chai, {Chee Yin} and Chang, {Tsuey Yu} and Yin Sun and Cheng, {Chih Jen} and Shiue, {Yow Ling} and Su, {Shu Jem} and Cheng, {Hong Lin} and Hsiao-Sheng Liu and Chow, {Nan Haw}",
year = "2013",
month = "9",
day = "1",
doi = "10.1016/j.ajpath.2013.05.015",
language = "English",
volume = "183",
pages = "709--719",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "3",

}

Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract. / Wang, Yi Wen; Li, Wei Ming; Wu, Wen Jeng; Chai, Chee Yin; Chang, Tsuey Yu; Sun, Yin; Cheng, Chih Jen; Shiue, Yow Ling; Su, Shu Jem; Cheng, Hong Lin; Liu, Hsiao-Sheng; Chow, Nan Haw.

In: American Journal of Pathology, Vol. 183, No. 3, 01.09.2013, p. 709-719.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract

AU - Wang, Yi Wen

AU - Li, Wei Ming

AU - Wu, Wen Jeng

AU - Chai, Chee Yin

AU - Chang, Tsuey Yu

AU - Sun, Yin

AU - Cheng, Chih Jen

AU - Shiue, Yow Ling

AU - Su, Shu Jem

AU - Cheng, Hong Lin

AU - Liu, Hsiao-Sheng

AU - Chow, Nan Haw

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Upper urinary tract urothelial carcinoma is a relatively uncommon disease and is diagnosed more frequently at advanced stages. The prognosis of these patients mainly has been related to tumor stage and grade. As a result, the definition of prognostic indicators enabling precise patient selection is mandatory for neoadjuvant or adjuvant therapies. The epithelial membrane protein (EMP2) was identified as one of the up-regulated genes by isoflavones. EMP2 overexpression suppressed foci formation, anchorage-independent growth in vitro, and tumorigenicity in severe combined immunodeficiency mice (all P < 0.05). In addition, a cross-talk between EMP2 and integrins αV and β3 was shown in the regulation of cell adhesion and migration. Higher EMP2 expression was associated with a better progression-free survival (P = 0.008) and cancer-related death (P < 0.001). EMP2 was identified as a tumor-suppressor gene in urinary tract urothelial carcinoma and may be an innovative co-targeting candidate for designing integrin-based cancer therapy.

AB - Upper urinary tract urothelial carcinoma is a relatively uncommon disease and is diagnosed more frequently at advanced stages. The prognosis of these patients mainly has been related to tumor stage and grade. As a result, the definition of prognostic indicators enabling precise patient selection is mandatory for neoadjuvant or adjuvant therapies. The epithelial membrane protein (EMP2) was identified as one of the up-regulated genes by isoflavones. EMP2 overexpression suppressed foci formation, anchorage-independent growth in vitro, and tumorigenicity in severe combined immunodeficiency mice (all P < 0.05). In addition, a cross-talk between EMP2 and integrins αV and β3 was shown in the regulation of cell adhesion and migration. Higher EMP2 expression was associated with a better progression-free survival (P = 0.008) and cancer-related death (P < 0.001). EMP2 was identified as a tumor-suppressor gene in urinary tract urothelial carcinoma and may be an innovative co-targeting candidate for designing integrin-based cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84883178589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883178589&partnerID=8YFLogxK

U2 - 10.1016/j.ajpath.2013.05.015

DO - 10.1016/j.ajpath.2013.05.015

M3 - Article

C2 - 23838430

AN - SCOPUS:84883178589

VL - 183

SP - 709

EP - 719

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

ER -